Aberrant RNA splicing as the molecular basis of some pathogenic variants
Received date: 2016-10-08
Revised date: 2016-12-02
Online published: 2016-12-07
Supported by
the Key Program of Shandong Provincial Natural Science Foundation, China(ZR2015HZ002)
Identification and correct classification of disease-associated mutations are essential for molecular diagnosis and clinical management of many genetic disorders. Although next-generation sequencing has greatly accelerated the detection of nucleotide changes, the biological interpretation of most variants has become a real challenge. Moreover, attention is typically paid to protein-coding changes and the potential impact of exonic variants on RNA splicing is often ignored. There is increasing evidence showing that disease-causing aberrant RNA splicing is more widespread than currently appreciated. Here, we review the major types of the variants involved in RNA splicing and the approaches used to identify and characterize these variants. We hope to provide a reference for evaluation of the effects of mutations on diseases.
Key words： RNA splicing; gene diagnosis; gene mutation
Yongxin Zou,Yaoqin Gong . Aberrant RNA splicing as the molecular basis of some pathogenic variants[J]. Hereditas(Beijing), 2017 , 39(3) : 200 -207 . DOI: 10.16288/j.yczz.16-336
| [1] | Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet, 2016, 53(3): 145-151. |
| [2] | Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer, 2007, 121(2): 225-231. |
| [3] | Padgett RA. New connections between splicing and human disease. Trends Genet, 2012, 28(4): 147-154. |
| [4] | Ars E, Serra E, García J, Kruyer H, Gaona A, Lázaro C, Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet, 2000, 9(2): 237-247. |
| [5] | Soukarieh O, Gaildrat P, Hamieh M, Drouet A, Baert-Desurmont S, Frébourg T, Tosi M, Martins A. Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools. PLoS Genet, 2016, 12(1): e1005756. |
| [6] | Daguenet E, Dujardin G, Valcárcel J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep, 2015, 16(12): 1640-1655. |
| [7] | Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med, 2012, 18(8): 472-482. |
| [8] | Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Mu?oz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol, 2013, 14(3): 153-165. |
| [9] | Svenson IK, Ashley-Koch AE, Gaskell PC, Riney TJ, Cumming WJK, Kingston HM, Hogan EL, Boustany RMN, Vance JM, Nance MA, Pericak-Vance MA, Marchuk DA. Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. Am J Hum Genet, 2001, 68(5): 1077-1085. |
| [10] | Teraoka SN, Telatar M, Becker-Catania S, Liang T, ?nengüt S, Tolun A, Chessa L, Sanal ?, Bernatowska E, Gatti RA, Concannon P. Splicing defects in the ataxia-telangiectasia gene,ATM: underlying mutations and consequences. Am J Hum Genet, 1999, 64(6): 1617-1631. |
| [11] | Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GM. A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet, 1998, 62(3): 713-715. |
| [12] | Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet, 2001, 27(1): 55-58. |
| [13] | Messiaen L, Callens T, De Paepe A, Craen M, Mortier G. Characterisation of two different nonsense mutations, C6792A and C6792G, causing skipping of exon 37 in the NF1 gene. Hum Genet, 1997, 101(1): 75-80. |
| [14] |